Prevention and Treatment of Urothelial Premalignant and Malignant Lesions

REFERENCES

• Spruck CHI, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784–8.
   Google Scholar
• Jones PA, Droller MJ. Pathways of development and progression in bladder cancer: New correlations between clinical observations and molecular mechan-isms. Semin Urol 1993; 11: 177–92.
   PubMedGoogle Scholar
• Hellsten S, Berg T, Wehlin L. Unrecognized renal cell carcinoma: clinical and diagnostic aspects. Scand J Urol Nephrol 1981; 15: 269–72.
   Google Scholar
• Franks LM. Latent carcinoma of the prostate. J Pathol Bacteriol 1954; 68: 603.
   PubMedGoogle Scholar
• Messing E, Catalona W. Urothelial tumors of the urinary tract. In: Walsh PC, Retik A, Vaughan ED, Wein A, eds. Campbell's urology, 7th edn. Philadel-phia, PA: WB Saunders, 1998: 2354.
   Google Scholar
• Jewett HJ, Strong GH. Infiltrating carcinoma of the bladder: relation of the depth of penetration of the bladder wall to incidence of local extension and metastasis. J Urol 1946; 55: 366–72.
   PubMed Web of Science ®Google Scholar
• Schoenberg M, Peralta C, Kiemeney LALM, Fleischer L. A contemporary analysis of superficial bladder cancer monitoring: the Johns Hopkins experience (1977–1997). J Urol 2000; 163 (Suppl): 152.
   Google Scholar
• Heney NM, Ahmed S, Flanagan MI, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083–6.
   PubMed Web of Science ®Google Scholar
• Malmström PU, Busch C, Norlen BJ. Recurrence, progression and survival in bladder cancer. A retro- spective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol 1987; 21: 185–95.
   Google Scholar
• Dalbagni G, Herr H. Current use and questions concerning intravesical BCG for superficial bladder cancer. Urol Clin N Am 2000; 27: 137–46.
   PubMed Web of Science ®Google Scholar
• Lamm DL. Carcinoma in situ. Urol Clin N Am 1992; 19: 499–508.
   PubMed Web of Science ®Google Scholar
• Herr NM. Tumor progression and survival in patients with T1G3 bladder tumors: 15-year outcome. Br J Urol 1997; 80: 762–5.
   PubMedGoogle Scholar
• Cookson MS, Sarosdy MF. Management of stage T I superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol 1992; 148: 797–801.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Ous S, Espetveit S, Langmark F. Patterns of primary care and survival in 336 consecutive un-selected Norwegian patients with bladder cancer. Scand J Urol Nephrol 1992; 26: 131–8.
   PubMed Web of Science ®Google Scholar
• Parmar MK, Freedman LS, Hargreave TB. Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council (Urological Cancer Working Party). J Urol 1989; 142: 284–8.
   Google Scholar
• Morris SB, Gordon EM, Shearer RJ, Woodhouse CR. Superficial bladder cancer: for how long should a tumour-free patient have check cystoscopies? Br J Urol 1995; 75: 193–6.
   PubMedGoogle Scholar
• Holmäng S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progres- sion and prognosis of patients with stages Ta and Ti transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995; 153: 1823–7.
   Google Scholar
• Thompson Jr RA, Campbell Jr EW, Kramer HC, Jacobs SC, Naslund MJ. Late invasive recurrence despite long-term surveillance for superficial bladder cancer. J Urol 1993; 149: 1010–1.
   PubMed Web of Science ®Google Scholar
• McCahy PJ, Harris CA, Neal DE. The accuracy of recording of occupational history in patients with bladder cancer. Br J Urol 1997; 79: 91–3.
   Google Scholar
• Sorahan T, Hamilton L, Wallace DMA, Bathers S, Gardiner K, Harrington JM. Occupational urothelial tumours: a regional case controlled study. Br J Urol 1998; 82: 25–32.
   PubMedGoogle Scholar
• Halachmi S, Linn JF, Amiel GE, Moskovitz B, Nativ O. Urine cytology, tumour markers and bladder cancer. Br J Urol 1998; 82: 647–54.
   Google Scholar
• Epstein JI, Amin MB, Reuter VR, Mostofi FK, and the Bladder Consensus Conference Committee. The World Health Organisation/International Society of Urologi-cal Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder. Am J Surg Pathol 1998; 22: 1435–48.
   Google Scholar
• Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999; 23: 443–7.
   PubMed Web of Science ®Google Scholar
• Cheng L, Cheville JC, Neumann RM, Bostwick DG. Flat intraepithelial lesions of the urinary bladder. Cancer 2000; 88: 625–31.
   PubMed Web of Science ®Google Scholar
• Hudson MA, Herr HW. Cancer in situ of the bladder. J Urol 1995; 153: 564–72.
   PubMed Web of Science ®Google Scholar
• Murphy WM. Falsely positive urinary cytology: pathologist's error or preclinical cancer? J Urol 1977; 118: 811–3.
   PubMed Web of Science ®Google Scholar
• Smith NW, Strutton GM, Walsh MD, Wright GR, Seymour GJ, Lavin MF, et al. Transferrin receptor expression in primary superficial human bladder tumours identifies patients who develop recurrences. Br J Urol 1990; 65: 339–44.
   PubMedGoogle Scholar
• Tut VM, Hildreth AJ, Kumar M, Mellon JK. Does voided urine cytology have biological significance? Br J Urol 1998; 82: 655–9.
   PubMedGoogle Scholar
• Chow N, Tzai T, Cheng H, Chan SH, Lin JSN. Urinary cytodiagnosis: can it have a different prognostic implication than a diagnostic test? Urol Int 1994; 53: 18–23.
   Google Scholar
• Bringuier PP, Umbras R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993; 53: 3241–5.
   PubMed Web of Science ®Google Scholar
• Lipponen PK, Eskelinen MJ. Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Pathol 1995; 175: 203–10.
   PubMed Web of Science ®Google Scholar
• Smith G, Elton RA, Beynon LL, Newsam JE, Chisholm GD, Hargreave TB. Prognostic results of normal looking mucosa in cases of superficial bladder cancer. Br J Urol 1983; 55: 665–9.
   PubMedGoogle Scholar
• Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger A, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med 1992; 326: 737–40.
   PubMed Web of Science ®Google Scholar
• Lunec J, Challen C, Wright C, Mellon JK, Neal DE. C-erbB-2 amplification and identical p53 mutations in concomitant transitional cell carcinomas of renal pelvis and urinary bladder. Lancet 1992; 339: 439–40.
   Google Scholar
• Harris AL, Neal DE. Bladder cancer-field versus clonal origin [editorial comment]. N Engl J Med 1992; 326: 759–61.
   PubMed Web of Science ®Google Scholar
• Knowles MA. The genetics of transitional cell carci-noma: progress and potential clinical application. Br J Urol Int 1999; 84: 412–27.
   Google Scholar
• Witjes JA, Kiemeney LALM, Verbeek ALM, Heij-broek RP, DeBruyne FMJ. Random bladder biopsies and the risk of recurrent superficial bladder cancer-a prospective study in 1026 patients. World J Urol 1992; 10: 231–4.
   Google Scholar
• Murphy WM, Miller AW. Cytology in the detection and follow-up of urothelial tumors. In: Javadpour N, ed. Bladder cancer. Baltimore, MD: Williams & Wilkins, 1984: 100–22.
   Google Scholar
• Schwalb DM, Herr HW, Fair WR. The management of clinically unconfirmed positive urinary cytology. J Urol 1993; 150: 1751–6.
   Google Scholar
• Schwalb MD, Herr HW, Sogani PC, Russo P, Sheinfeld J, Fair WR. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence. J Urol 1994; 152: 382–7.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Cote RJ, Sauter G. Genetic and molecular markers of urothelial premalignancy and malignancy. Scand J Urol Nephrol 2000; 34 (Suppl 205): 82–93.
   Google Scholar
• Grossman HB, Schmitz-Dräger B, Fradet Y, Tribukait B. Use of markers in defining urothelial premalignant and malignant conditions. Scand J Urol Nephrol 2000; 34 (Suppl 205): 94–104.
   Google Scholar
• Buzzeo BD, Heisey DM, Messing EM. Bladder cancer in renal transplant recipients. Urol 1997; 50: 525–8.
   Google Scholar
• Swindle P, Falk M, Rigby R, Petrie J, Hawley C, Nicol D. Transitional cell carcinoma in renal transplant recipients: the influence of compound analgesics. Br J Urol 1998; 81: 229–33.
   PubMedGoogle Scholar
• Lomax-Smith JD, Seymour AE. Neoplasia in analgesic nephropathy. A urothelial field change. Am J Surg Pathol 1980; 4: 565–72.
   PubMed Web of Science ®Google Scholar
• Jones HC, Swinney J. Thiotepa in the treatment of tumours of the bladder. Lancet 1961; 2: 615–8.
   PubMed Web of Science ®Google Scholar
• Oosterlinck W, Kurth KH, Schroder F, et al. and Members of the European Organization for Research and Treatment of Cancer Genitourinary Group. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, Ti papillary carcinoma of the bladder. J Urol 1993; 149: 749–52.
   Google Scholar
• Bouffioux C, Kurth K-H, Bono A, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol 1995; 153: 934–41.
   Google Scholar
• Lamm DL, Riggs DR, Traynelis CL, et al. Apparent failure of current intravesical chemotherapy prophyl-axis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995; 153: 1444–50.
   PubMed Web of Science ®Google Scholar
• Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treat-ment of stage TaT1 bladder cancer. J Urol 1996; 156: 1934–41.
   PubMed Web of Science ®Google Scholar
• Pagano F, Bassi P. Milani C, et al. A low dose Bacillus Calmette-Gurérin regimen in superficial bladder cancer therapy: is it effective? J Urol 1991; 146: 32–5.
   PubMed Web of Science ®Google Scholar
• Losa A, Hurle R, Lembo A. Low dose Bacillus Calmette-Guerin for carcinoma in situ of the bladder: Long-term results. J Urol 2000; 163: 68–72.
   Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance Bacillus Calmette-Guerin immuno-therapy for recurrent Ta, Ti and carcinoma in situ transitional cell carcinoma of the bladder: a rando-mized Southwest Oncology Group study. J Urol 2000; 163: 1124–9.
   PubMed Web of Science ®Google Scholar
• Lamm DL. Bacillus Calmette-Gurein immunotherapy for bladder cancer. J Urol 1985; 134: 40–7.
   PubMed Web of Science ®Google Scholar
• Herr HW, Laudone VP, Badalament RA, et al. BCG alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 1450–5.
   PubMed Web of Science ®Google Scholar
• Herr HW. Transurethral resection and intravesical therapy of superficial bladder tumours. Urol Clin N Am 1991; 18: 525–8.
   PubMed Web of Science ®Google Scholar
• Herr HW, Schwalb DM, Zhang ZF, et al. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995; 13: 1404–8.
   PubMed Web of Science ®Google Scholar
• Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000; 163: 60–2.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG. Complications of bacillus Calmette-Guérin immuno-therapy in 1278 patients with bladder cancer. J Urol 1986; 135: 272–4.
   PubMed Web of Science ®Google Scholar
• De Balincourt CIand the EORTC GU group. Relation-ship between efficacy and side effects of BCG instillations in TA-Ti bladder cancer: Results of EORTC trial 30911. J Urol 1999; 161: 284.
   Google Scholar
• Krege S, Giani G, Meyer R, Otto T, Rubben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating clinics. J Urol 1996; 156: 962–6.
   Google Scholar
• Martinez-Pineiro JA, Jiminez Leon J, Martinez-Pineiro L, et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: A randomized study in 202 patients with superficial bladder cancer. J Urol 1990; 143: 502–6.
   Google Scholar
• Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with Bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205–9.
   PubMed Web of Science ®Google Scholar
• Debruyne FMJ, van der Meijden APM, Witjes JA, et al. Bacillus Calmette-Guerin versus mitomycin C intravesical therapy in superficial bladder cancer. Urology 1992; 40 (Suppl): 11–5.
   Google Scholar
• Lundholm C, Norlen BJ, Liman P. et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 1996; 156: 372–6.
   Google Scholar
• Witjes JA, van der Meijden APM, Witjes WPJ, et al. A randomized prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Eur J Cancer 1993; 29A: 1672–6.
   PubMed Web of Science ®Google Scholar
• Witjes JA, van der Meijden APM, Collette L, Sylvester R, Debruyne FMJ, van Aubel A, the EORTC GU Group and the Dutch South East Cooperative Urolo-gical Group. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. Urology 1998; 52: 403–10.
   Google Scholar
• Witjes JA, Canis CTM, Mungan NA, Debruyne FMJ, Witjes WPJ. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and Bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol 1998; 160: 1668–72.
   Google Scholar
• Rintala E, Jauhiainen K, Kaasinen E, Nurmi M, Affihan O, and Finnbladder Group. Alternating mito- mycin C and bacillus Calmette-Guérin instillation prophylaxis for recurrent papillary (stages Ta to Ti) superficial bladder cancer. J Urol 1996; 156: 56–60.
   Google Scholar
• Wijkström H, Kasinen E, and The Urothelial Cancer Group of the Nordic Association of Urology. A Nordic study comparing intravesical instillations of alternating mitomycin C and BCG with BCG alone in carcinoma in situ of the urinary bladder. J Urol 1999; 161 (Suppl): 286.
   Google Scholar
• Naito S, Kotoh S, Omoto T, et al. Prophylactic intravesical instillation chemotherapy against recur- rence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicine alone. Cancer Chemother Pharmacol 1998; 42: 367–72.
   PubMed Web of Science ®Google Scholar
• Rohde D, Raffenberg G, Kaviani S, Wolff J, Jakse G. T-N-(12-(2-(gamma-L-glutamylamino)-ethyThdithio)- ethylymitomycin C (KW-2149) is more active thanmitomycin C on chemonaive and drug-resistant urothelial carcinoma cells. Urol Res 1998; 26: 243–7.
   Google Scholar
• Munns J, Yaxley J, Coomer J, Lavin MF, Gardiner RA, Walters D. Evaluation of the potential of transferrin-adriamycin conjugates in the treatment of bladder cancer. Br J Cancer 1998; 82: 284–9.
   Google Scholar
• Riedl CR, Knoll M, Plas E, Piluger H. Intravesical electromotive drug administration technique: prelimin- ary results and side effects. J Urol 1998; 159: 1851–6.
   PubMed Web of Science ®Google Scholar
• Glashan RAW. A controlled randomized trial of intravesical alpha-2-beta interferon in carcinoma in situ of the bladder. J Urol 1990; 144: 658–61.
   PubMed Web of Science ®Google Scholar
• Boccardo F, Cannata D, Rubagotti A, et al. Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2-beta: results of a multicentric Italian study. J Clin Oncol 1994; 12: 7–13.
   PubMed Web of Science ®Google Scholar
• Williams RD, Gleason DM, Smith AY, Zinner N, et al. Pilot study of intravesical alpha-2-b interferon for treatment of bladder carcinoma in situ following BCG-failure. J Urol 1996; 155(Suppl): 494A.
   Google Scholar
• O'Donnel MA, Downs TM, DeWolf WC. Preliminary phase 2 results of combination BCG plus interferon. alfa-2b in high risk patients with superficial bladder cancer. J Urol 1999; 161(Suppl): 286.
   Google Scholar
• Lamm DL, Morales A, Grossman HB, Bruce L, Swerdlow R, Habicht K. KLH immunotherapy of papillary and in situ transitional cell carcinoma of the bladder: a multicenter phase I-II clinical trial. J Urol 1996; 155(Suppl): 662A.
   Google Scholar
• Sasaki H, Schmitt D, Hayashi Y, Pollard B, Suzuki F. Induction of interleukin 3 and tumor resistance by SSM, a cancer immunotherapeutic agent extracted from M. tuberculosi. Cancer Res 1990; 50: 4032–7.
   Google Scholar
• Merguerian PA, Donahue L, Cockett ATK. Intralum-inal interleukin-2 and Bacillus Calmette-Guérin for treatment of bladder cancer: A preliminary report. J Urol 1987; 137: 216–9.
   Google Scholar
• Herman JR, Lerner SP. Current status of gene therapy for prostate and bladder cancer. Int J Urol 1997; 4: 435–40.
   PubMedGoogle Scholar
• Jones A, Crew J. Vascular endothelial growth factor and its correlation with superficial bladdder cancer recurrence rates and stage progression. Urol Clin N Am 2000; 27: 191–7.
   PubMed Web of Science ®Google Scholar
• Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF. Clinical results of the transurethral resection and evaluation of superficial bladder carci-nomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol 1999; 13: 117–21.
   PubMed Web of Science ®Google Scholar
• Rosenkilde-Olsen P, Wolf H, Schroeder T, Fischer A, Hojgaard K. Urothelial atypia and survival rate of 500 unselected patients with primary transitional cell tumour of the urinary bladder. Scand J Urol Nephrol 1988; 22: 257–63.
   Google Scholar
• Baithun SI, Rogers HS, Martin JE, Zuk RJ, Blandy JP. Primary dysplasia of the bladder. Lancet 1988; i: 483.
   Google Scholar
• Murphy WM, Busch C, Algaba F. Intraepithelial lesions of urinary bladder: morphological considera-tions. Scand J Urol Nephrol 2000; 34(Suppl 205): 67–81.
   PubMedGoogle Scholar
• Smith JA, Labasky RF, Cockett ATK, et al. Bladder Cancer Clinical Guidelines Panel: Report on the management of non-muscle invasive bladder cancer (Stages Ta, Ti and TIS). J Urol 1999; 162: 1697–701.
   PubMed Web of Science ®Google Scholar
• Malmström P-U. Personal communication..
   Google Scholar
• Bedwani R, Renganathan E, El-Kwhsky F, Braga C, Abu-Seif IIH, Abul-Azm T, et al. Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt. Br J Cancer 1998; 77: 1186–9.
   PubMed Web of Science ®Google Scholar
• O'Flynn JD, Mullaney J. Vesical leukoplakia progres-sing to carcinoma. Br J Urol 1974; 46: 31–7.
   PubMedGoogle Scholar
• Morgan RJ, Cameron KM. Vesical leukoplakia. Br J Urol 1980; 52: 96–100.
   PubMedGoogle Scholar
• Amin MB. Flat intraepithelial lesions of the urinary bladder. In: Young RH, ed. Urologic surgical pathol-ogy for the practicing pathologist. Boston, MA: Harvard Medical School and Massachusetts General Hospital, 1999: 1–30.
   Google Scholar
• Messing EM, Vaillancourt A. Hematuria screening for bladder cancer. J Occup Med 1990; 32: 838–45.
   PubMedGoogle Scholar
• Schröder FH. Microscopic haematuria requires inves-tigation. Br Med J 1994; 309: 70–2.
   PubMed Web of Science ®Google Scholar
• Fracchia JA, Motta J, Miller LS, Armenakas NA, Schulmann GB, Greenberg RA. Evaluation of asymp-tomatic microhematuria. Urology 1995; 46: 484–9.
   PubMed Web of Science ®Google Scholar
• Grossfeld GD, Carroll PR. Evaluation of asymptomatic microscopic hematuria. Urol Clin N Am 1998; 25: 661–76.
   PubMed Web of Science ®Google Scholar
• Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000; 163: 524–7.
   Google Scholar
• Whelan P, Brutton JP, Dowell AC. Three-year follow-up of bladder tumours found on screening. Br J Urol 1993; 72: 893–6.
   Google Scholar
• Jollier M, Messing EM. Detection, diagnosis and natural history of bladder cancer. Curr Opin Urol 1994; 4: 269–74.
   Google Scholar
• Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton BA, Bram LL, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presenta-tions. Urology 1995; 45: 387–96.
   PubMed Web of Science ®Google Scholar
• Mayfield MP, Whelan P. Bladder tumours detected on screening: results at 7 years. Br J Urol 1998; 82: 825–8.
   PubMedGoogle Scholar
• McNicholas MM, Raptopoulos VD, Schwartz RK, Sheiman RG, Zormpala A, Prassopoulos PK, et al. Excretory phase CT urography for opacification of the urinary collecting system. AJR Am J Roentgenol 1998; 170: 1261–7.
   PubMed Web of Science ®Google Scholar
• Denholm SW, Conn IG, Newsam JE, Chisholm GD. Morbidity following cystoscopy: comparison of flex-ible and rigid techniques. Br J Urol 1990; 66: 152–4.
   PubMedGoogle Scholar
• Hvidi V. Feldt-Rasmussen K. Primary tumours in the renal pelvis and ureter with particular attention to the diagnostic problems. Acta Chir Scand 1973; 433 (Suppl): 91–101.
   Google Scholar
• Prout Jr GR. Classification and staging of bladder carcinoma. Cancer 1980; 45: 1832–41.
   Web of Science ®Google Scholar
• Kakizoe T, Fujita J, Murase T, Matsumoto K, Kishi K. Transitional cell carcinoma of the bladder in patients with renal pelvic and ureteral cancer. J Urol 1980; 124: 17–9.
   Google Scholar
• Palou J, Salvador J, Milian F, Collado A, Algaba F, Vicente J. Management of superficial transitional cell carcinoma in the intramural ureter: what to do? J Urol 2000; 163: 744–7.
   PubMed Web of Science ®Google Scholar
• Abel PD, Hall RR, Williams G. Should pT1 transi-tional cell cancers of the bladder still be classified as superficial? Br J Urol 1988; 62: 235–9.
   Google Scholar
• Gammelgaard PA, Sorensen BL. The Copenhagen bladder cancer project. In: Pavone-Macaluso M, Smith PHP, eds. Bladder tumours and other topics in uro-logical oncology. London: Plenum Press, 1978: 113–5.
   Google Scholar
• Heney NM, Nocks BN, Daly JJ, Prout Jr GR, Newall JP, Griffin PP, et al. Ta and Ti bladder cancer: loca-tion, recurrence and progression. Br J Urol 1982; 54: 152–7.
   Google Scholar
• Prout GR Jr, Barton BA, Griffin PP, Friedell GH. Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J Urol 1992; 148: 1413–9.
   Google Scholar
• Li B, Kanamaru H, Noriki S, Yamaguchi T, Fukuda M, Okada K. Reciprocal expression of bc1-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder. Urol Res 1998; 26: 235–41.
   PubMedGoogle Scholar
• Wolf H, Hojgaard K. Urothelial dysplasia concomitant with bladder tumours as a determinant factor with future new occurrences. Lancet 1983; ii (8342): 134–6.
   Google Scholar
• Witjes JA, Kiemeney LALM, Oosterhof GON, Debruyne FMJ. Prognostic factors in superficial bladder cancer. Eur Urol 1992; 21: 89–97.
   PubMed Web of Science ®Google Scholar
• Holmäng S, Hedelin H, Anderström C, Holmberg E, Johansson SL. Long-term followup of a bladder carcinoma cohort: routine followup urography is not necessary. J Urol 1998; 160: 45–8.
   Google Scholar
• Amar AD, Das S. Upper urinary tract transitional cell carcinoma in patients with bladder carcinoma and associated vesicoureteric reflux. J Urol 1985; 133: 468–71.
   PubMed Web of Science ®Google Scholar
• Miller EB, Eure GR, Schellhammer PF. Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG. Urology 1993; 42: 26–30.
   Google Scholar
• Schellhammer PF, Ladaga LE, Moriarty RP. Infra-vesical Bacillus Calmette-Guerin for superficial transi-tional cell carcinoma of the prostate urethra in association with carcinoma of the bladder. J Urol 1995; 153: 53–6.
   Google Scholar
• Althausen AF, Prout Jr GR, Dal B. Non-invasive papillary carcinoma of the bladder associated with carcinoma in-situ. J Urol 1982; 127: 849–54.
   PubMed Web of Science ®Google Scholar
• Kriegmair M, Baumgartner R, Kntichel R, Stepp H, Hofstädter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996; 155: 105–10.
   Google Scholar
• Akaza H, Kurth KIT, Hinotsu S, Jewett MAS, Naito K, Okada K, et al. Intravesicle chemotherapy and immunotherapy for superficial tumors: basic mechan- ism of action and future direction. Urol Oncol 1998; 4: 121–9.
   PubMedGoogle Scholar
• Kellof GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Sigman CC. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res 1994; 54(Suppl): 2015–24.
   Google Scholar
• Mirvish SS. Effects of vitamins C and E on N-nitroso compound formation, carcinogenesis, and cancer. Cancer 1986; 58: 1842–50.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Riggs DR, Shriver JS, Van Gilder PE, Roch if, DeHaven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994; 151: 21–6.
   Google Scholar
• Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10–25.
   PubMed Web of Science ®Google Scholar
• Mettlin C, Graham S. Dietary risk factors in human bladder cancer. Am J Epidemiol 1979; 110: 255–63.
   PubMed Web of Science ®Google Scholar
• Eichholzer M, Stahelin HB, Gey KF, Ludin E, Bemasconi F. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 1996; 66: 145–50.
   Google Scholar
• Studer UE, Jenzer S, Biedermann C, Chollet D, Kraft R, von Toggenburg H, et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 1995; 28: 284–90.
   Google Scholar
• Cohen SM, Wittenberg If, Bryan GT. Effect of avitaminosis A and hypervitaminosis A on urinary bladder carcinogenicity of N-[4-(5-nitro-2-fury1)-2-thiazolyl] formamide. Cancer Res 1976; 36: 2334–9.
   Google Scholar
• Sporn MB, Squire RA, Brown CC, Smith IM, Wenk ML, Springer S. 13-cis-Retinoic acid: inhibition of bladder carcinogenesis in the rat. Science 1977; 195: 487–9.
   PubMed Web of Science ®Google Scholar
• Grubbs CJ, Moon RC, Squire RA, Farrow GM, Stinson SF, Goodan DG, et al. 13-cis Retinoic acid: inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl) nitrosamine. Science 1977; 198: 743–6.
   PubMed Web of Science ®Google Scholar
• Murasaki G, Miyata Y, Babaya K, Atai M, Fukushima S, Ito N. Inhibitory effect of an aromatic retinoic acid analog on urinary bladder carcinogenesis in rats treated with N-butyl-N-(4-hydroxybutyl) nitrosamine. Gann 1980; 71: 333–40.
   PubMedGoogle Scholar
• Moon RC, McCormick DL, Becci PJ, Shealy YF, Frickel F, Paust J, et al. Influence of 15 retinoic acid amides on urinary bladder carcinogenesis in the mouse. Carcinogenesis 1982; 3: 1469–72.
   PubMed Web of Science ®Google Scholar
• Pollard M, Luckert PH, Sporn MB. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl) retinamide. Cancer Res 1991; 51: 3610–1.
   Google Scholar
• Brown RR, Price IM, Satter EJ, Wear JB. The metab-olism of tryptophan in patients with bladder cancer. Acta Int J Cancer 1960; 16: 299–303.
   PubMed Web of Science ®Google Scholar
• Byar D, Blachard C. Comparisons of placebo, pyri-doxine and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 1977; 10: 556–61.
   PubMedGoogle Scholar
• Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I, et al. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of Scand J Urol Nephrol Suppl 205 a prospective, randomized phase III study performed by the EORTC GU group. Eur Urol 1975; 27: 110–6.
   Google Scholar
• Schlegel JU. Proposed uses of ascorbic acid in the prevention of bladder carcinoma. Ann NY Acad Sci 1975; 258: 432–7.
   PubMed Web of Science ®Google Scholar
• Grubbs CJ, Juliana MM, Eto I, Casebelt T, Whitaber LM, Canfield GJ, et al. Chemoprevention by indo- methacin of N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder tumors. Anticancer Res 1993; 13: 33–6.
   PubMed Web of Science ®Google Scholar
• Okajima E, Ozono S, Endo T, Majima T, Tsutsumi M, Fukuda T, et al. Chemopreventive efficacy of pirox- icam administered alone or in combination with lycopene and b-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxy-butyl) nitrosamine treatment. Jpn J Cancer Res 1997; 88: 543–52.
   PubMedGoogle Scholar
• Klan R, Knispel HH, Meier T. Acetylsalicylic acid inhibition of N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder carcinogenesis in rats. J. Cancer Res Clin Oncol 1993; 119: 482–5.
   Google Scholar
• Okajima E, Denda A, Ozono S, Takahama M, Aka H, Sasaki Y, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the devel-opment of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine. Cancer Res 1998; 588: 3028–31.
   Google Scholar
• Grossman HB. Personal communication.
   Google Scholar
• Herzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, alpha-tocopherol, beta-carotenem retinol, and subsequent bladder cancer. Cancer Res 1989; 49: 6144–8.
   Google Scholar
• Homma Y, Kakizoe T, Samma S, Oyasu R. Inhibition of N-butyl-N-(4-hydroxybutyl) nitrosamine-induced rat urinary bladder carcinogenesis by difluoromethyl-omithine. Cancer Res 1987; 47: 6167–79.
   Web of Science ®Google Scholar
• Loprinzi CL, Messing EM, O'Fallon JR, Poon MA, Love RR, Quella SK, et al. Toxicity evaluation of difluoromethylomithine: doses for chemopreventiontrials. Cancer Epidemiol Biomark Prey 1996; 5: 371–4.
   PubMed Web of Science ®Google Scholar
• Sasnowski JT, Lamm DL. Immunotherapy for bladder cancer. In: Rous SN, ed. Urology Annual. East Norwalk, CT: Appleton and Lange, 1990: 123–5.
   Google Scholar
• Sarosdy MF, Lamm DL, Williams RD. Phase I trial of oral bropirimine in superficial bladder cancer. J Urol 1992; 147: 31–3.
   Google Scholar
• Witjes WP, Konig M, Boeminghaus FP, et al. Results of a European comparative randomized study compar- ing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. Eur Urol 1999; 36: 576–81.
   PubMed Web of Science ®Google Scholar
• Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S, et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur Urol 1995; 27: 104–9.
   PubMed Web of Science ®Google Scholar
• Stadler WM, Sherman J, Bohlander SK, Roulston D, Dreyling M, Ruckstalis D, et al. Homozygous deletions within chromosome bands 9p 21-22 in bladder cancer. Cancer Res 1992; 54: 2060–3.
   Web of Science ®Google Scholar
• Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992; 52: 1393–8.
   PubMed Web of Science ®Google Scholar
• Saito S, Bannerji R, Gansbacher B, Rosenthal FM, Romanenko P. Heston WDW, et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 1994; 54: 3516–20.
   Google Scholar
• Wingo PA, Ries LA, Giovino GA, Miller DS, Rosenberg JIM, Shopland DR, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999; 91: 675–90.
   PubMed Web of Science ®Google Scholar
• Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med 1994; 154: 169–75.
   PubMedGoogle Scholar
• Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, et al. Smoking cessation: decreased risk of stroke in women. JAMA 1993; 269: 232–6.
   PubMed Web of Science ®Google Scholar
• Fleshner N, Garland J, Moadel A, Herr H, Ostroff J, Trambert R, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer 1999; 86: 2337–45.
   PubMed Web of Science ®Google Scholar
• LaRue H, Allard P. Simoneau M, Normand C, Pfister C, Moore L, et al. P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. Carcinogenesis 2000; 21: 101–6.
   PubMed Web of Science ®Google Scholar
• Hennekens CH. Update on aspirin in the treatment and prevention of cardiovascular disease. Am Heart J 1999; 137: S9—S13.
   PubMed Web of Science ®Google Scholar
• Marnett U. Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Prevent Med 1995; 24: 103–6.
   PubMed Web of Science ®Google Scholar
• Steineck G, Gerhardsson de Verdier M, Wiholm B-E. Acetaminophen, some other drugs, some diseases, and the risk of transitional cell carcinoma. Acta Oncol 1995; 34: 741–8.
   Google Scholar
• Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Curhan GC, Willett WC, et al. Fluid intake and the risk of bladder cancer in men. N Engl J Med 1999; 340: 1390–7.
   PubMed Web of Science ®Google Scholar
• Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath Jr CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097–105.
   Google Scholar
• Cadman D, Chambers L, Feldman W, Sackett D. Assessing the effectiveness of community screening programs. JAMA 1984; 251: 1580–5.
   PubMed Web of Science ®Google Scholar
• Kryger JV, Messing E. Bladder cancer screening. Semin Oncol 1996; 23: 585–97.
   PubMed Web of Science ®Google Scholar
• Froom P. Froom J, Ribak J. Asymptomatic micro-scopic hematuria—is investigation necessary? J Clin Epidemiol 1997; 50: 1197–200.
   Google Scholar
• Messing EM, Young TB, Hunt VB, Emoto SE, Wehbie JM. The significance of asymptomatic microhematuria in men 50 or more years old. Findings of a home screening study using urinary dipsticks. J Urol 1989; 137: 919–25.
   Google Scholar